The global Paroxysmal Supraventricular Tachycardia (PSVT) market is set for significant growth, driven by advancements in diagnostics and treatment, and rising cardiovascular awareness. Key factors ...

CHICAGO -- The novel intranasal agent etripamil was safe and rapidly converted most patients with paroxysmal supraventricular tachycardia (PSVT) back into normal rhythm, the phase II NODE-1 trial ...

Milestone Pharmaceuticals has raised $55 million to take a cardiovascular disease asset through phase 3. The series C tees Milestone up to test its intranasal calcium channel blocker etripamil in ...

It is the end of the day, and you have finished your last case in the electrophysiology laboratory. On your way to speak with the patient's family, an eager young house officer stops you in the ...

Cardamyst (etripamil) is a nose spray that helps treat sudden episodes of fast heartbeats, known as paroxysmal supraventricular tachycardia (PSVT). PSVT is a type of abnormal heart rhythm where your ...

MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of ...

Up to 2 million people in the U.S. experience rapid-fire heartbeats from time to time, and many end up in the hospital for treatment. But an investigational nasal spray may help folks with paroxysmal ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...

CHICAGO, IL — A nasal spray containing the calcium-channel blocker etripamil could allow patients to convert acute paroxysmal supraventricular tachycardia (PSVT) outside the hospital, phase 2 data ...

A clinical trial led by Weill Cornell Medicine investigators showed that a nasal spray that patients administer at home, without a physician, successfully and safely treated recurrent episodes of a ...